|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0004083,
umls-concept:C0005684,
umls-concept:C0008976,
umls-concept:C0013216,
umls-concept:C0030705,
umls-concept:C0034656,
umls-concept:C0045093,
umls-concept:C0087111,
umls-concept:C0144576,
umls-concept:C0205132,
umls-concept:C0205179,
umls-concept:C0205436,
umls-concept:C0278627,
umls-concept:C0282461,
umls-concept:C0439590,
umls-concept:C1556085
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2011-1-31
|
|
pubmed:abstractText |
The second-line chemotherapeutic treatment for metastatic urothelial cancer (UC) after failure of cisplatin-based first-line therapy needs to be improved. Based on encouraging phase II data of gemcitabine and paclitaxel (Taxol) (GP), this trial was designed to compare a short-term (arm A) versus a prolonged (arm B) second-line combination chemotherapy of GP.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1569-8041
|
|
pubmed:author |
pubmed-author:AUO Bladder Cancer Group,
pubmed-author:AlbersPP,
pubmed-author:FechnerGG,
pubmed-author:FimmersRR,
pubmed-author:HeidenreichAA,
pubmed-author:HeimbachDD,
pubmed-author:LehmannJJ,
pubmed-author:NiegischGG,
pubmed-author:ParkS-ISI,
pubmed-author:SienerRR,
pubmed-author:SteinerUU
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
22
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
288-94
|
|
pubmed:meshHeading |
pubmed-meshheading:20682548-Adult,
pubmed-meshheading:20682548-Aged,
pubmed-meshheading:20682548-Aged, 80 and over,
pubmed-meshheading:20682548-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20682548-Carcinoma, Transitional Cell,
pubmed-meshheading:20682548-Deoxycytidine,
pubmed-meshheading:20682548-Disease Progression,
pubmed-meshheading:20682548-Disease-Free Survival,
pubmed-meshheading:20682548-Humans,
pubmed-meshheading:20682548-Middle Aged,
pubmed-meshheading:20682548-Paclitaxel,
pubmed-meshheading:20682548-Prognosis,
pubmed-meshheading:20682548-Urinary Bladder Neoplasms
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99].
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Clinical Trial, Phase III
|
